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ABSTRACT The aim of this study was to develop a freeze-dried buccal tablet for the rapid 
delivery of naloxone in opioid overdose.  The tablet composition was optimized to produce an 
amorphous matrix, which was confirmed by the absence of peaks associated with crystallinity 
observed by differential scanning calorimetry and powder X-ray diffraction. Tablets with high 
gelatin content lacked adequate porosity. Mannitol was added to the formulation to bridge and 
intercalate gelatin’s tight polymer aggregates, however sodium bicarbonate was also required to 
prevent crystallization within the tablets. A linear reduction in mannitol’s re-crystallization 
enthalpy was observed with increasing sodium bicarbonate concentration (Δre-cryH = -
20.3[NaHCO3] + 220.9; r
2
 = 0.9, n = 18). The minimum sodium bicarbonate concentration for 
full inhibition of mannitol crystallization was 10.9% w/w. Freeze dried tablets with lower 
amounts of sodium bicarbonate possessed a crystalline fraction that PXRD identified as mannitol 
hemihydrate from the unique peak at 9.7° 2θ. Mannitol’s greater affinity for both ions and 
residual water rather than its affinity for self-association was the mechanism for the inhibition of 
crystallization observed here. The optimized tablet (composition mannitol 24% w/w (4.26 mg), 
gelatin 65% w/w (11.7 mg), sodium bicarbonate 11% w/w (1.98 mg) and naloxone 800 µg) 
formed predominantly amorphous tablets that disintegrated in less than 10 s.  Optimized tablets 
were chemically and physically stable over 9 months storage at 25°C. As speed of drug 
liberation is the critical performance attribute for a solid dosage form designed to deliver drug in 
an emergency, a novel imaging based in vitro disintegration assay for buccal tablets was 
developed.  The assay was optimized with regard to conditions in the buccal cavity: i.e. 
temperature 33-37°C, volume of medium (0.1-0.7 mL) and use of mucin-containing biorelevant 
medium. The disintegration assay was sensitive to temperature, medium volume and medium 
composition; naloxone tablet disintegration was extremely rapid, with full disintegration ranging 
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from 5-20 seconds. In conclusion, rapidly disintegrating tablets have been developed which are 
suitable for proof-of-concept clinical trial in humans to determine the pharmacokinetics of 
naloxone delivered via the buccal route. 
INTRODUCTION 
Opioid overdose causes an estimated 69,000 deaths per annum and is a major contributor to the 
global burden of disease [1]. Naloxone is a highly effective opioid antagonist but must be 
delivered rapidly to the systemic circulation of overdose victims, who may be unconscious, so as 
to prevent fatal outcome from respiratory depression [2]. Naloxone is a highly water soluble drug 
and has a LogP of 2.09 and pKa above 7 (Table 1). Existing published pharmacokinetic–
pharmacodynamics studies of naloxone do not enable simple determination of the appropriate 
dose required to achieve a target concentration or concentration–time profile to maximize its 
antidote efficacy [3]. Speed of onset is critical to reverse the life-threatening respiratory 
depression which characterizes the opioid overdose [3]. Naloxone injection is currently licensed 
for intravenous (IV) and intramuscular (IM) administration and is available in two 
concentrations, 0.4 mg/mL and 1 mg/mL injectable solution.  Licensing of naloxone has recently 
changed in the UK to expand access to naloxone as a medicine which is available in emergency 
situations [4].  Making naloxone available as an emergency medicine is in accordance with the 
position statements of the American Academy of Clinical Toxicology, the American College of 
Medical Toxicology, the American Association of Poison Control Centers [5], the American 
Medical Association [6] and the World Health Organization [7].  However, the use of injections 
in emergency situations is limited by the training required to administer these, ideally using 
aseptic technique, and syringes are not readily portable [8, 9]. Orally ingested dosage forms are 
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unsuitable as they are not easily administered to an unconscious patient and naloxone undergoes 
extensive first pass metabolism and has low bioavailability (< 1%) after oral administration [10]. 
 
Prototype improvised kits for nasal administration have been introduced in ambulance services 
and clinical trials, but the use of nasal naloxone remains off-licence as supporting 
pharmacokinetic data is lacking . There are reasons for caution about reliance on nasal naloxone, 
and concerns about the clinical adaptation of untested unlicensed formulations have been 
expressed [11].Other non-injectable options need to be considered. 
 
Buccal delivery provides an attractive alternative route of administration for the emergency 
delivery of drugs [12-14]. The application of a tablet to the inner cheeks of the oral cavity is 
simple and easily accessible to a non-specialist bystanders or healthcare professionals in 
emergency situations [12]. Following naloxone liberation from the dosage form, the buccal 
mucosa, a 40-50 cell (500-600 µm) thick stratified epithelium, provides the principal absorption 
barrier [15].  The vasculature of the buccal mucosa drains into the retromandibular, lingual and 
facial veins, which in turn drain directly into the internal jugular vein and, via the superior vena 
cava, into the systemic circulation [12, 16, 17].  The absorption of naloxone from the human 
buccal cavity is unknown, but the bioavailability of naloxone from the buccal administration in 
rats has been reported to be 70%, compared to 0.3% via the oral route due to the extensive first 
pass metabolism [10], with maximum plasma levels obtained within 15 min [10].  Sublingual 
administration of 2-8 mg of naloxone solution has been reported to precipitate opiate withdrawal 
in humans within 30 min [18].
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Dosage forms for buccal delivery include (i) tablets and lozenges, (ii) films, wafers and patches, 
(iii) liquids, creams, gels, ointments, (iv) sprays, lozenges, chewing gum and mucoadhesive film 
[19]. Of these options, tablets provide the simplest, most portable and easily applied formulation 
as an emergency medicine, but for efficacy will be required to disintegrate immediately on 
application.  Orally disintegrating tablets have recently become widely accepted dosage forms, 
especially for pediatric and geriatric patients and there are more than 55 products having 
marketing authorization in the United States, European Union and Japan [20]. However, despite 
their rapid disintegration, dissolution times for drugs from these formulations is often in minutes 
rather than seconds [21]. Development of formulations with ‘instant’ disintegration rates (e.g. ≤ 
10 s) is required for emergency medicines; one strategy to achieve this is to exploit the 
physicochemical advantages of amorphous materials, which enhance disintegration rate and 
bioavailability due to their increased molecular mobility compared to corresponding crystalline 
material [22, 23]. However, a major problem with producing and maintaining amorphous form in 
a product is physical and chemical instability, i.e. reversion to crystalline structure [24, 25]. 
Production of solid amorphous medicines is typically complex because the quality attributes of 
the final product are difficult to control, which has proved a limitation for many early phase 
amorphous formulations entering clinical trials [26].
 
The aim of this study was to develop a safe, easily administered and quick-to-act buccal tablet 
containing naloxone. Table 2 summarizes the ideal or target properties of a buccal tablet for the 
emergency delivery of naloxone. A novel instant disintegrating tablet formulation was designed 
by modifying the ratio of gelatin, sodium bicarbonate and mannitol to produce an amorphous, 
but stable tablet by freeze drying. Freeze drying is frequently used as a manufacturing technique 
for pharmaceuticals, its application to instant disintegrating tablets, also referred to as freeze 
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dried wafers, is an established technology, e.g. an example known as Zydis
®
 was 
commercialized in 1993 [27]. However, due to the ending of the Zydis
®
 related patent, there has 
been an increase in the research activity associated with this dosage form, and other forms of 
freeze dried wafers and tablets [16, 21, 28]. Such research activity has created the need for better 
and more relevant methods for evaluating the performance of freeze dried systems, especially 
orally and instant disintegrating tablets. The authors consider that this evaluation must include 
the characterization of solid-state behavior and the measurement of disintegration times under 
more bio-relevant conditions than the current pharmacopeia methods describe. 
The principles of molecular and material science [29] were used to design a formulation and 
manufacturing process that confers structural and physicochemical properties for optimal 
stability and performance.  Speed of drug liberation is the critical performance or quality 
attribute for a solid dosage form designed to deliver drug in an emergency.  At present there is 
not a pharmacopoeia method for quantifying disintegration for instant disintegrating tablets [16, 
21, 28].  Therefore a buccal disintegration test was developed which proved to be: (i) 
discriminatory for quality control purposes, and (ii) bio-relevant with potential for future 
development as an assay to predict in-vivo performance. 
 
MATERIALS & METHODS 
MANUFACTURE OF INSTANT DISINTEGRATING TABLETS OF NALOXONE HCl 
Instant disintegrating tablets were produced in the Pharmacy Manufacturing Unit of Guy’s 
Hospital of the Guy’s and St Thomas’ NHS Foundation Trust. The materials control, 
manufacture and testing of the tablets were performed under Good Manufacturing Practice 
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conditions at the MHRA licensed manufacturing facility at GSTT (Authorization number: 
11387). All equipment and instruments were calibrated, tested and maintained in accordance 
with ICH guidelines [30]. Feed solution for tablet preparation was prepared by disintegrating 
0.780 g of pre-weighed gelatin powder (Fagron Ltd, 110 g bloom strength), 0.132 g of sodium 
bicarbonate powder (Fagron Ltd) and 2.931 g of mannitol 10 (Fresenius Kabi) in 40 mL of water 
for injection (WFI) held at 70°C. Once all excipients were fully dissolved, a further 40 mL WFI 
(room temperature) was added and the solution was allowed to cool to room temperature. 
Naloxone hydrochloride dihydrate (pharm-grade; Fagron Ltd) 0.0586 g was dissolved in the feed 
solution, which was made up to 100 mL. The same method was used in preparing feed solutions 
with varying mannitol:gelatin ratios, where the weights of each of the excipients were adjusted 
accordingly. 
 
Empty wells of an aluminium blister (Zhejang Xinfei Machinery Ltd), made and designed 
specifically for this study, were filled with 1.500 g of naloxone HCl feed solution. Filled blister 
wells were cooled down to -20°C to allow feed solutions to freeze and then were maintained at -
20°C, above its primary glass transition (Tg’), for a 2 h annealing step. After annealing, the 
blisters were cooled down to -80°C. Frozen tablets where removed from the wells and placed 
into pre-cooled freeze drying vials (1 oz Clear Glass Universal Type 1) packed inside a 
temperature controlled freeze drying chamber, -40°C, and the drying chamber was sealed. A 
Bench top (Lyotrap freeze dryer; LTE Scientific Ltd). was used to perform the freeze drying 
cycle. This freeze dryer model does not provide shelf heating option, therefore a 5 day freeze 
drying cycle was initiated to ensure all ice within the tablets was sublimed under ≤ 0.01 mbar 
and ≤ -40°C [31]. At the end of the freeze drying cycle, the drying chamber was backfilled with 
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nitrogen, allowing it to reach atmospheric pressure with the cooling unit on. The drying chamber 
was opened and the freeze drying vials were immediately sealed with rubber stoppers and screw 
lids while inside the drying chamber. The finished products were removed from inside the drying 
chamber and inspected for breakage or shrinkage. 
 
Quality control tests were performed on each of three batches of manufactured tablets to ensure 
that they matched specification limits given in table 4. The critical limits were set to comply with 
the requirements of the British Pharmacopeia and European Pharmacopeia for oral dosage forms 
(mass/content/physiochemical properties). While other limits; such as dimensions, are for 
guidance, and are not required by the BP. Thus they have been set broadly, see table 4, and will 
likely be refined upon scale up and technology transfer of the process. Whilst the target yield 
was 20 units per batch; at each test point/event 10% of the batch was tested. Where two tablets 
from each batch were tested for the uniformity of weight and dimensions (using a digital 
calliper) and disintegration time using an adapted USP disintegration method; the method 
involved placing two tablets into a 25 mL water bath at 37°C
 
and observing their disintegration, 
making a total of 6 tablets used for each test. Full tablet disintegration was classified for this USP 
disintegration test as the absence of particulate matter, i.e. a clear solution, achieved within 3 
minutes or 180 seconds.  
 
NALOXONE HCl HPLC ASSAY
 
A published reverse phase HPLC assay for naloxone HCl was used to confirm chemical stability 
[32]. The method utilized a C-18 Gemini-NX 5 µm reverse phase column, mobile phase of 32% 
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v/v methanol HPLC grade and 68% 0.1 ammonium acetate (pH 5.8), isocratic flow rate of 1 
mL/min, column temp of 37°C and an injection volume of 20 µL. Absorbance was measured at 
229 nm.  
DIFFERENTIAL SCANNING CALORIMETRY 
Differential scanning calorimetry studies were performed over a temperature range of -40 to 
200°C using a DSC Q20 (TA Instruments, New Castle, DE, USA) with a refrigerated cooling 
accessory (RCS). The DSC cell was purged with 50 cm
3
/min dry nitrogen and the RCS was 
purged with 150 cm
3
/min nitrogen. The DSC cell was calibrated following the instrument 
manufacturer’s guidelines.  Experimental conditions for freeze dried tablets followed an 
equilibration at 25°C for 5 min, ramp to 200°C (10°C/min), followed by a ramp to 25°C 
(10°C/min) and a ramp to 200°C (10°C/min).  Samples were analyzed in aluminium pin-holed 
hermetic pans. All experiments were repeated three times. The sample size used was 
approximately 5 mg, with the mass for each experiment recorded accurately on a six-figure 
balance, (Micro balance: Sartorius UK Ltd). 
Experimental conditions for sub ambient differential scanning calorimetry studies on feed 
solutions followed an equilibration at 25°C for 5 min, ramp to -40°C (10°C/min), followed by 
ramp to 25°C (10°C/min).    
EVIRONMENTAL SCANNING ELECTRON MICROSCOPY 
Samples were adhered to a conventional SEM stub and imaged using a FEI Quanta 200F 
microscope. The operating conditions were: vacuum pressure 200 Pa, HV 20kV, a gaseous 
secondary detector and a typical magnification of ×1000. 
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POWDER X-RAY DIFFRACTION (PXRD) 
PXRD analyses were performed on Rigaku MiniFlex 600 diffractometer (Rigaku, Tokyo, Japan). 
The samples were spread on a zero background holder and placed on a spinner stage. The 
instrument produces Cu Kα radiation (1.5418 Å) operated at a voltage of 40 kV and a current of 
15 mA over a scan range 3-40° 2θ with a step size of 0.01° 2θ at a speed of 5°/min. 
 
DIGITAL IMAGE DISINTEGRATION ASSAY 
A digital image or photographic disintegration assay was developed to measure tablet 
disintegration in small volumes of medium in temperature controlled blisters.  Disintegration was 
quantified using a gel imager to follow tablet disappearance.  The disintegration vessel was a 
thermal-jacketed aluminium blister sheet with black-painted wells of the same dimension as 
those used for manufacturing the tablets (Figure 1).  Disintegration medium was phosphate 
buffered distilled water (pH 7.3 ± 0.2) or a synthetic saliva adapted from the SS5 USP recipe for 
artificial saliva [33], which consisted of distilled water, salts (NaCl = 8 g/L, KH2PO4 = 0.19 g/L 
and Na2HPO4 = 2.38 g/L) and mucin 2.16 g/L (from porcine stomach).   
 
Assay temperature was adjusted by placing the whole apparatus in a temperature controlled 
water bath at the target temperature. Disintegration medium, 0.7 mL, was pipetted into the blister 
wells adjacent to the test well and micro probe thermocouples connected to a data logger 
thermometer were used to monitor the temperature of the disintegration medium. Once the 
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temperature of the disintegration medium in blister wells reached the target temperature the 
apparatus was placed inside a heat-insulting box of polystyrene and transferred into a closed box 
gel imager for the disintegration assay. This apparatus allowed accurate temperature logging 
throughout the disintegration assay to ensure the temperature of the disintegration medium was 
maintained ± 1°C of the target temperature.   
 
Disintegration was measured using a GeneSnap version 6.07.03 gel imager, with the camera 
located above test blister well. A reference image was then taken of test blister well containing 
disintegration medium, after which the well was dried and an instant disintegrating tablet was 
placed in the blister. An image of test well was then taken (t = 0 s) and the assay initiated by 
adding the required volume of temperature-conditioned disintegration medium onto the tablet, 
(e.g., 0.7 mL at 35°C) after which 100 consecutive images were taken at 0.4 s intervals. Image J 
analysis software, was used to analyze the images by determining the mean grey value (MGV), 










Ratios of mannitol, gelatin and sodium bicarbonate were varied with the aim of identifying a 
tablet composition that would form an amorphous and porous freeze-dried product to meet the 
ideal properties described in table 2. Mannitol was utilized because of its hydrophilic nature, 
bulking properties and common use as a lyoprotectant [27]. Gelatin was selected to confer the 
ideal quality attributes for a successful product that meets the target properties of an ideal instant 
disintegrating tablet (Please refer to table 2 for the ideal properties); i.e. gelatin typically forms 
glassy amorphous complexes with relatively high glass transition temperatures, Tg 50-90°C, 
provides structural strength and has mucoadhesive properties [12, 27].
 
In the process of defining the collapse temperature of freeze-dried feed solutions, the behavior of 
a series of test formulation solutions were characterized during freezing by DSC; where the 
effects of varying the ratio of mannitol:gelatin on the Tg’ of the aqueous solutions were 
investigated in the presence of sodium bicarbonate, a disintegrating agent, which reduced the Tg’ 
of pure gelatin aqueous solutions by 14°C (Table 3). Results showed that high percentages of 
gelatin, in the test aqueous solutions, contributed to raising the Tg’, as test solutions with the 
lowest mannitol:gelatin ratio showed the highest Tg’ (Table 3). Based on the Tg’ values presented 
in table 3, the primary drying temperature was maintained well below the lowest Tg’, of -25°C 
shown by all of the test formulations. Thus the temperature within the freeze drying chamber was 
always below Tg’  and the collapse temperature, approximately 2ºC > Tg’  [34].   
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Preliminary results showed that simply freeze drying aqueous solutions of pure mannitol and 
pure gelatin produced tablets of very poor quality.  Freeze dried tablets composed of 100% w/w 
mannitol possessed a distinct melting peak with an average onset at 163.9 ± 0.5°C (n=3), 
indicative of a crystal melt (Figure 2). A small endotherm at approximately 60°C for 100% w/w 
freeze-dried mannitol was representative of the hemihydrate crystalline form of mannitol [35], 
indicating that freeze drying a solution of pure mannitol produced a crystalline product.  
Comparable studies have demonstrated that freeze dried mannitol contains a mixture of the 
hemihydrate together with the anhydrous polymorphs as mannitol hemihydrate is quite unstable 
[35, 36]. The melting points for the α and β polymorphs are very close together and have been 
reported to fall between 165 and 166°C [37, 38]. A lower onset for this melting peak of 
approximately 164°C indicates the presence of an additional phase. Further inspection of the 
leading edge of the endothermic peak revealed a very small and broad inflexion overlaid on the 
rapidly falling heat flow curve. Nunes et al. have attributed this broadening of the peak onset to 
conversion of an anhydrous δ polymorph to the β form of mannitol. Dehydration of the 
hemihydrate form mannitol at 60°C initiates the formation of the δ polymorph [35].  The δ 
polymorph is enantiotropic and thus will undergo transition to the more stable β form over quite 
a wide temperature range, typically from 140 to 180°C with a relatively small peak area when 
observed by DSC, thus it is often difficult to identify this transition [38].
 
 
Pure mannitol crystalline tablets were brittle and difficult to remove from their sample vials 
without collapsing into a powder. In contrast, pure gelatin tablets had a sticky texture and lacked 
porosity.  Formulations containing both mannitol and gelatin proved successful when freeze-
dried; addition of gelatin diminished the crystalline melting peak in the freeze-dried product 
 14 
whereas mannitol conferred porosity within the tablets. However, even with high gelatin content, 
persistent peaks were observed in the amorphous halo of the powder x-ray diffraction results. 
This indicated a crystalline fraction within the freeze-dried tablet and the unique peak at 9.7° 2θ 
identified the presence of mannitol hemihydrate [35], an example of this unambiguous peak can 
be seen in Figure 3a. 
 
Since mannitol has an affinity for inorganic salts and this miscibility often leads to the inhibition 
of mannitol crystallization when present in freeze dried solids [38], sodium bicarbonate was 
introduced as a ternary agent. Physical mixtures of mannitol and sodium bicarbonate were 
investigated by heating to 200°C to melt the mannitol, then analyzed by DSC while cooling at 
10°C/min back to room temperature. The addition of sodium bicarbonate reduced the size of the 
mannitol re-crystallization peak in the cooling cycle.  At concentrations of sodium bicarbonate 
above 10% w/w, crystallization of mannitol could no longer be seen. The reduction in the 
observed mannitol re-crystallization enthalpy was linear with increasing sodium bicarbonate 
concentration (Δre-cryH = -20.3[NaHCO3] + 220.9; r
2
 = 0.9, n = 18). The extrapolated line crossed 
the enthalpy axis at a concentration of sodium bicarbonate at approximately 10.9% w/w 
(supporting information; Figure S1), indicating that this is the concentration of sodium 
bicarbonate at which crystallization of mannitol is inhibited entirely. Therefore, unless otherwise 
stated all freeze dried tablets were formulated to contain 11% w/w sodium bicarbonate. Scanning 
electron microscopy images revealed that the inclusion of sodium bicarbonate resulted in an 
increase in pore size but a reduction in the thickness of the pore walls compared to tablets 
prepared without sodium bicarbonate (data not shown). 
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The effect of mannitol:gelatin ratio on the crystallinity of the tablet was screened using 
differential scanning calorimetry.  As the proportion of mannitol reduced relative to gelatin, 
progressively broader peaks with a reduced area appeared at lower temperatures.  Peaks were 
entirely absent from formulations containing < 24% w/w mannitol (Figure 2). These 
observations were confirmed by X-ray diffraction (Figure 3a) indicating that the freeze-dried 
product containing 24% w/w mannitol and 11% w/w sodium bicarbonate was fully amorphous.  
Characterisation of the tablet excipients by PXRD showed distinct peaks for mannitol, naloxone 
and sodium bicarbonate, but no peaks for gelatin (Figure 3b).  Thus, an optimized formulation, 
with a composition of 24% w/w mannitol, 65% w/w gelatin and 11% w/w sodium bicarbonate 
was defined and this has shown to meet ideal disintegration rate and optimal stability as 
described in table 2.  These tablets were also confirmed to be predominately amorphous by 




TABLET SPECIFICATION AND STABILITY 
The instant disintegrating buccal tablets conformed reproducibly to quality specifications for 
weight, size, speed of disintegration and drug content (Table 4).  The white hemispherical porous 
tablets were 29.4 ± 0.2 mm in length, 16.1 ± 0.5 mm in width with a depth of 3.0 ± 0.2 mm and 
weighed 17.7 ± 0.4 mg (Figure 4).  Scanning electron microscopy (Figure 4) revealed the pore 
size in the tablet to have an average length of 0.23 ±0.02 mm(SE) and an average width of 0.094 
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±0.01 mm (SE), n=20. The target drug content, 800 µg of Naloxone HCl/tablet and chemical 
stability over 9 months when stored under nitrogen at 4°C or 25°C were confirmed by HPLC 
assay.  The residual moisture content of the tablets was 10.4 ± 3.2% w/w, which is relatively 
high but it did not result in chemical degradation of the API or physical instability (Table 4). 
 
IN VITRO DISINTEGRATION ASSAY FOR BUCCAL TABLETS  
Imaging freeze-dried tablets using the adapted gel imager was relatively straightforward. Tablets 
of the optimized naloxone formulation appeared white but once the disintegration media had 
been added, a clear solution very rapidly developed revealing the black painted surface of the 
blister well beneath. For example, adding 0.7 mL of phosphate buffer to a naloxone tablet, with 
the temperature of the blister well held at 37°C, resulted in approximately half of the matrix 
remaining at 2s and by 10s the matrix had disappeared, figure 1. For the digital imaging 
disintegration assay the limit or target for tablet disintegration was classified as the time taken to 
achieve 10% of the matrix remaining or 90% disintegration. This target was met for the 
optimized naloxone tablets, under the conditions of 37°C and 0.7 mL, at 4.8 ± 0.6 seconds and 
furthermore by 10 seconds only 6% of the matrix remained, figure 5a & 5b. It should be noted 
that a very small amount of white colour remained in the images recorded at the end of 
disintegration assay. This was attributed to small air bubbles remaining in the solution and 
internal reflection at the curved edge of the blister well resulting from the position of the light 
sources. No particulate matter was seen when the contents of the blister well, from a typical 
naloxone tablet experiment, were viewed under a light microscope. Even under high 
magnification only air bubbles in a clear solution were observed. When the phosphate buffer was 
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replaced with artificial saliva, the very small amount of residual white colour was further 
diminished at the end of the naloxone tablets’ disintegration. The surface-active nature of the 
mucin present in the saliva dispersed the air bubbles, and thus the percentage of matrix 
remaining fell to a reading of approximately zero, figure 5c.  
        The novel digital imaging disintegration assay was used to explore the effects of 
temperature, solvent volume and composition on the disintegration of the tablets. Under all 
conditions the tablets disintegrated fully (>90%) within 30 s.  Tablets disintegrated in < 10 s in 
0.7 mL of phosphate buffer at 35°C (Figure 5a).  Temperature variation over the range reported 
to exist in the buccal cavity [39], 33-37°C did not alter the disintegration rate, but the rate was 4-
5 times slower at 25°C.  In opiate overdose, the volume of oral fluid available in the buccal 
cavity may be reduced compared to 0.7 mL in a typical adult human [28]. Reducing the amount 
of fluid available to the tablet progressively reduced the rate at which the tablet disintegrated, 
with disintegration in 0.1 mL being 4.5 times slower than in 0.7 mL (Figure 4b).  Interestingly, 
when phosphate buffer was replaced with synthetic saliva, a slightly quicker disintegration rate 
was observed, a result of better spreading and wetting of the tablet caused by the mucin present 
in the disintegration medium (Figure 5b). 
Evaluating the discrimination between disintegration profiles, measured at different temperatures 
and volumes, was performed using the similarity factor (f2) test [40]. This approach was applied 
because of the high number of data points recorded for each disintegration profile; therefore 
making other common statistical approaches, for example the MANOVE analysis, impractical. 
This analysis confirmed that the digital imaging disintegration assay disintegration profiles were 
sensitive to the volume of disintegration medium used, for example the f2 value comparing 
between a disintegration volume of 0.7 and 0.4 mL at 35°C was 28.36, (for this statistical 
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approach an f2 value below 50 indicates low similarity or in other words a significant difference 
between the two profiles of data). Interestingly the profiles at different temperatures, indicated a 
high similarity for disintegration between 33, 35 and 37°C, as all comparisons had f2 values 
equal or greater than 50, with only the profiles recorded at 25°C showing a statistical difference 
to the rest of the data set. 
To validate the digital imaging disintegration assay, the marketed freeze-dried and orally 
disintegrating tablet, Imodium Instant® was investigated using 0.7 mL of phosphate buffer at 
37°C. Imodium Instant® tablets showed slower disintegration compared to the naloxone tablets 
and failed to meet the target with 46.0 ± 0.2 % of the matrix remaining after 30 seconds, 
supporting information, Figure S2. Light microscopy aided the validation because it showed that 
the much higher percentage of the matrix remaining, detected in the disintegration assay, was 
caused by the presence of aggregated particles. 
 
DISCUSSION 
An instant disintegrating tablet aiming to rapidly deliver  naloxone HCl was developed for a 
planned clinical trial associated with the emergency buccal delivery of an opioid antagonist in 
opioid overdose. The product is suitable for proof of concept clinical trials in humans to 
determine the pharmacokinetics of naloxone delivered via this route. The size and shape of the 
developed tablet were designed to ensure a high surface area contact with the buccal epithelium. 
The open pore structure and amorphous nature of the low density tablet, 11.8 ± 0.3 × 10
-3
 g/mL, 
were designed for rapid release of drug in low volumes of fluid. Additionally, the size and shape 
of the tablet were fashioned based on the recommendations of healthcare professionals 
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experienced in treating overdose patients [27]. These dimensions contrast with smaller orally 
disintegrating tablets currently marketed, for example Imodium Instants® have a diameter of 7.5 
mm [27]. The developed naloxone instant disintegrating tablet is larger, at a length of 29 mm and 
a width of 16 mm to make it easier to insert into the buccal cavity of an unconscious patient 
using a fingertip.       
 
A tablet specification was developed for weight, dimensions, rate of disintegration and drug 
content and used to verify batch-to-batch reproducibility and stability (table 4).  Batch-to-batch 
verification was performed by testing 10% from each of 3 batches. However, this was repeated 
10 times over the course of a 9 month stability study, thus all units within the 3 batches were 
tested to verify batch-to-batch. Tablets containing 24% w/w mannitol showed no shrinkage or 
collapse from their dimensions after the initial freezing step, confirming that the Tg’ of the 
formulation was not exceeded during the drying cycle. If the Tg’ of mannitol in maximally freeze 
concentrated aqueous solutions is exceeded during drying, collapse and crystallization of the 
amorphous cake is observed as a dramatic shrinkage of the product [36]. Mannitol in freeze 
drying solutions was shown to crystallize at temperatures close to -25°C (Table 3) [31]. The 
addition of small amounts of salt stabilized amorphous mannitol produced from freeze 
concentrated solutions by raising the primary glass transition by 2 degrees (Table 3) [31]; hence 
sodium bicarbonate was included in the tablet matrix of this study [31]. Furthermore, the 
inclusion of sodium bicarbonate enhanced the porosity of freeze dried material.  
One of the roles of gelatin in the formulation is to raise the glass transition of both the freeze 
concentrated solution and the dried amorphous product in which gelatin maintains the 
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amorphous structure.  The drying cycle reported within this paper is conservative, incorporating 
a wide safety margin; when considering scale up and increasing process efficiency, the drying 
temperature of -40°C could be increased.  
 
Gelatin alone was insufficient to prevent crystallization of mannitol within the tablet during 
freeze drying. Even at 65% w/w gelatin, sodium bicarbonate was required to eliminate the 
persistent PXRD peak, indicative of the crystalline hemihydrate form of mannitol. This peak 
disappeared when 5% sodium bicarbonate was added to the feed solution. However, 
measurement of re-crystallization during the cool cycle using DSC revealed that concentration of 
sodium bicarbonate for full suppression of crystallization was 11% w/w. Thermal analysis, 
especially DSC, is influenced less by particle size and density issues compared to PXRD because 
the whole of the crystalline fraction present in the sample contributes to the response observed 
[41]. Thus DSC was more sensitive for determining the concentration of sodium bicarbonate 
needed to prevent mannitol crystallization. When salts are present in freeze concentrated 
solutions of mannitol, the sugar has a greater affinity for ions and water, than with itself and thus 
the formation of mannitol crystals is inhibited. However water is key to this mechanism; removal 
of a large proportion of the non-frozen water during secondary drying and this protective effect 
is lost and mannitol crystals are observed [38]. Thus secondary drying was negated in the 
preparation of the tablets reported here and a longer primary drying cycle was applied. This 
resulted in 10% w/w residual water content for the tablets that maintained their amorphous 
structure but did not adversely influence the stability of the product. 
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A wide range of mannitol to gelatin concentration ratios were investigated to allow selection of a 
predominantly amorphous formulation for further investigation. Gelatin acts as a binder and 
provides structural strength, resistance to breakage and a highly porous spongy structure [27]. 
Too much gelatin can have a negative effect on the rate of disintegration and dissolution as a 
result of inter-molecular interactions between the polymer chains of gelatin, through both 
hydrogen bonding and steric hindrance [12]. Both mannitol and salts are incorporated within 
freeze-dried materials to bridge and intercalate these tight polymer aggregates and thus expand 
the porous structure [42]. Thus, high concentrations of gelatin in the formulation increase the 
likelihood of strong inter-polymer chain attractions, resulting in water trapping and the 
subsequent formation of gels [27]. Unlike other studies, for example Gugulothu et al. [27], where 
this problem was overcome by lowering the gelatin content and compensating with crystalline 
mannitol as a supporting agent, we have shown that it is possible to increase the ratio of gelatin 
to mannitol and form amorphous tablets (Figures 2 & 3). 
To circumvent the issue of strong gelatin intermolecular interaction, small amounts of an ionic 
salt, i.e. sodium bicarbonate, were used to expand the gelatin network, inhibit mannitol 
crystallization and generate an amorphous material [42].  This resulted in a fast disintegrating, 
gelatin-mannitol amorphous complex.  Gelatin may also play an important role in the long term 
stability of amorphous mannitol by increasing the glass transition of amorphous mannitol by 
approximately 13°C, as reported by Kim et al. [41] Mannitol in turn acts as a lyoprotectant agent 
for proteins and is thus believed to stabilize the porous structure of gelatin in freeze-dried 
formulations [38]. The stabilizing effect of mannitol in freeze drying decreases with an increase 
in mannitol crystallinity [43], which is avoided in the current product.  
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Mannitol polymorphs were clearly detected in the DSC thermograms for the tablets composed of 
non-optimal ratios of mannitol and gelatin.  For the crystalline containing samples, sodium 
bicarbonate also plays a significant role in the formation and thermal stability of the polymorphs 
observed. Telang et al. [38] have shown that salts will depress the melting points of mannitol 
polymorphs by up to 15°C, with additional broadening of the associated peaks. The complex 
thermal and PXRD results show that a mixture of the hemihydrate and β polymorphs are formed 
during freeze drying and the tablets are heated, de-hydration and conversion results in the 
observation of melting profiles for the δ & α polymorphs as well as the underlying β form. These 
transitions are broadened and depressed by the presence of sodium bicarbonate. 
 
There is no standard method for in vitro disintegration tests for instant disintegrating tablets. 
Many studies use standard USP apparatus 2 disintegration methods with a disintegration volume 
of 900 mL, whereas the total volume of saliva in the mouth does not usually exceed 3 mL [44]. 
Other studies have attempted to study disintegration by applying physical force to the tablet 
using a texture analyzer [45], in which case disintegration profiles are therefore dependent on 
mechanical strength of the tablet rather than its disintegration properties.  We report a novel and 
reproducible digital image disintegration assay to study rapidly disintegrating buccal tablets. The 
assay allows automated data collection to monitor tablet disintegration in a volume and 
temperature controlled environment, using conditions relevant to the buccal mucosa.  The 
disintegration of the tablet as a whole is used as a surrogate for drug release, and was rapid, 
economical, discriminatory and appropriate for the product developed.  A factor that may limit 
the wider application of the assay is its reliance on the disappearance of white colour as a 
measure of tablet disintegration, which would exclude its use for evaluating the disintegration of 
tablets with insoluble excipients. Combing image analysis algorithms, common to particle size 
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analysis, with our photographic approach to small volume disintegration is likely to remove this 
temporary limitation. 
Adapting the GeneSnap gel imager and the Image J analysis software for the quantification of 
tablet disintegration was able to provide the necessary level of detail within each image to 
quantify disintegration, as the following evidence demonstrates.  1) The disintegration assay 
successfully discriminated between ODT’s that fully disintegrated, e.g. the optimized naloxone 
formulation, and ODT’s that partially disintegrated, e.g. the Imodium Instant® tablets, in the 0.7 
mL of medium used to model the buccal cavity, figure 2s. 2) When the solution/dispersion 
generated by the disintegration assay was analyzed by light microscopy after 30 seconds, the 
optimized naloxone formulation formed a clear, particulate free solution, whereas the Imodium 
Instant tablet formed a dispersion of rectangular shaped crystals with an average length of 12 μm 
with an associated SE of 0.8 μm. Thus the novel image analysis approach could resolve partial 
disintegration when a dispersion of particles was formed as opposed to a clear solution, figure 2s. 
3) Each image that contributed to the individual time point within the disintegration profile was 
relatively large at 2.76 MB. Such a high resolution permitted a wide range of observed mean 
grey values that were used to determine the % of the matrix remaining and thus the disintegration 
times. For example, the mean MGV readings for a typical disintegration assay for the optimized 
naloxone formulation was 1770 ± 61 at the start, then 961 ± 56 at 3 seconds, 200 ± 5 at 10 
seconds and 191 ± 4 at 30 seconds, (these were mean values determined using three separate 
tablets tested under identical conditions, ± SE). MGV readings at 10 and 30 seconds were very 
close to the background reading for a blister well containing only disintegration medium. There 
was typically an order of magnitude reduction in the MGV readings from t zero to near complete 
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tablet disintegration, which is encouraging in terms of sensitivity towards quantifying tablet 
disintegration. 
The novel disintegration assay was optimized for temperature in the range of 33-37°C, 
corresponding to buccal temperature range [39], and for disintegration medium with a volume in 
the range of 0.1-0.7 mL corresponding to saliva volumes range (Figure 5) [46]. No significant 
differences were observed in the disintegration profile over the buccal temperature range, but 
profiles were significantly different when the test was conducted at 25°C (Figure 4a).  
Directly correlating the reduction in the mean grey value of a tablet’s image to the disintegration 
of its freeze-dried matrix is not without complexity. For wider applicability, it should be noted 
that the current version of the gel imager records only in black and white, thus disintegration is 
recorded as a disappearance of the colour white. For coloured tablets an appropriate colour filter 
may be used on the camera to enhance the contrast in the grey scale before conversion into a 
black and white image.  Another complicating factor is the inclusion of polymers that in their 
solid form are white but form translucent masses of high viscosity when exposed to water, e.g. 
cellulose based polymers, such as microcrystalline cellulose and hydroxyl propyl methyl 
cellulose. The authors would recommend in such cases that the image based disintegration assay 
should be augmented with inverted microscopy and the use of appropriate stains. For example, 
an aqueous based stain with an affinity for cellulose, e.g. the diazo dye, Congo Red, should be 
added to the blister well immediately after the disintegration assay. Congo red has a strong 
affinity for cellulose, therefore if aggregated cellulose polymers persist, the suggested stain 
would contrast boundaries and concentration gradients within the blister well. Thus if gel like 
structures are present, the use of inverted microscopy will allow detection of agglomerates that 
are small enough to permit an acceptable disintegration limit, or those extended aggregated 
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structures that indicate an absence of disintegration. The use of inverted microscopy allows these 
measurements to be conducted in-situ. Such elaboration on the digital imaging disintegration 
assay was unnecessary for the application reported in this paper because cellulose based 
polymers were not included in the naloxone tablet.  
 
CONCLUSION 
A novel amorphous instant disintegrating tablet, containing naloxone, was successfully produced 
to good manufacturing practice standards. The composition, based on three excipients, mannitol, 
gelatin and sodium bicarbonate, was essential for fulfilling the design aims for a naloxone instant 
disintegrating buccal tablet. The tablets were both chemically and physically stable for 9 months 
and may be used as a prototype in clinical trials for the instant buccal delivery of emergency 
naloxone.  A novel disintegration method for the instant disintegrating buccal tablets was 
developed and used to investigate the disintegration profile of the tablet formulations 
manufactured in this study. The test has potential for development as a quality control test for 
instantly disintegrating buccal tablets and, with further exploration of biorelevant test conditions, 
an assay that is predictive of in vivo performance.  Total disintegration of the naloxone buccal 
tablet was achieved in less than 10 s which is critical for their intended application.  
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Table 1. Details of the physical and chemical characteristics of Naloxone. Naloxone structure was constructed using 
ACD/ChemSketch.  
Molecular  Formula  C19H21NO4 [47]  
Structure of Naloxone 
 [47] 
Melting Range 200-205°C [48] 
Solubility Freely soluble in water, soluble in ethanol 
96%, practical insoluble in toluene [48] 
Log10 P (Octanol water partition coefficient)  2.09 [49] 
pKa 7.9 [49] 
Description White or almost white, crystalline powder, 
hygroscopic [50] 
 
Table 2 target properties of an ideal instant disintegrating tablet 
Property and description Target properties Limits 
Solid state Predominantly amorphous matrix Absence of peaks assisted with 
crystallinity in both DSC and PXRD 
90% Disintegration time < 10 seconds Based on BP limits for instant 
disintegrating tablets < 3min 
Drug content 0.8 mg Based on BP limits for naloxone 
injections 0.76-0.84 mg 







Physical stability; size, and 
disintegration time 
 
12 months , not less than a 5% 
change of the following: 
 
Size: Length: 26-30mm 
Width: 14-18mm 
90%Disintegration time < 10 s 
6 months , not less than a 5% change 
of the following: 
 
Size: Length: 26-30mm 
Width: 14-18mm 
90%Disintegration time < 10 s 
Chemical stability; Drug 
content 
12 months , not less than a 5% 
change of the following: 
 
Based on BP limits for naloxone 
injection  0.76-0.84 mg 
6 months , not less than a 5% change 
of the following: 
 
Based on BP limits  for naloxone 










Figure 1. Schematic for the digital image disintegration assay, constructed from an aluminium blister sheet with a painted black background to provide contrast 
for the tablet. Disintegration of the tablet was monitored as the mean grey value using an image analyser. Controlled temperature maybe altered, in the present 
study temperatures in the range between 25°C and 37°C were investigated.  
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Table 3 Primary glass transition temperatures (Tg’) of feed solutions containing varying concentrations of mannitol 
and gelatin in the absence and presence of sodium bicarbonate. The standard error is of  n=3   
Equivalent  to w/w% composition per tablet Average 
Tg’ /°C 
SE 
Mannitol Gelatin Sodium Bicarb 
0.0% 100.0% 0% -9.1 0.03 
0.0% 89.0% 11% -23.1 0.18 
24.0% 65.0% 11% -22.8 0.13 
44.5% 44.5% 11% -25.2 0.40 
65.0% 24.0% 11% -24.3 0.22 
89.0% 0.0% 11% -23.0 0.13 
100.0% 0.0% 0% -25.0 0.10 
 
 
Figure 2.  Differential scanning calorimetry to show the effect of mannitol:gelatin ratio on the thermal properties of 
the freeze dried instant disintegrating tablets.  The tablets were composed of mannitol:gelatin in the ratios illustrated, 
plus sodium bicarbonate 11% w/w, with the exception of the 100% w/w mannitol sample.   
 
 
























Figure 3.  (a) Powder X-ray diffraction to show the effect of mannitol:gelatin ratio on the solid state properties of the 
freeze dried instant disintegrating tablets.  The tablets were composed of mannitol:gelatin in the ratios specified, 
plus sodium bicarbonate 11% w/w. (b) Powder X-ray diffraction of individual tablet excipients, plus the formulated 
product with and without naloxone 800 µg. 












































Figure 4.  Top left, photograph of the naloxone instant disintegrating tablet with the length displayed in mm, top 
right showing the tablet’s intended method of dispensing to an unconscious patent’s buccal cavity. Bottom main 
image; presenting a scanning electron micrograph of the instant disintegrating tablet, with a smaller image to its tope 
left corner; showing porous structure at higher magnification. Average pore length = 0.23 ±0.017 mm (SE) and 




Figure 5.  Effect of (A) temperature [volume 0.7 mL; medium – phosphate buffered saline], (B) fluid volume [temperature 35oC; medium – 
phosphate buffered saline], (C) disintegration medium [temperature 35
o
C; volume 0.7 mL] on the disintegration profile of the naloxone 
instant disintegrating tablet ; using a digital image disintegration assay.  Data represent mean ± standard error, n=3. 












































































































   Stability  
  0 months 9 months 9 months 





Tablet weight (mg)  16.9 - 20.7 17.8 ± 0.5 17.8 ± 0.5 17.6 ± 0.5 
Dimension - length (mm) 26.0 - 30.0 29.4 ± 0.2 29.1 ± 0.3 29.1 ± 0.7 
Dimension - width (mm) 14.0 - 18.0 16.1 ± 0.5 16.1 ± 0.3 16.0 ± 0.3 
Disintegration test* (s) ≤180   14.0 ± 5.9   9.0 ± 5.0 10.0 ± 5.0 
Naloxone HCl assay (mg) 0.76 - 0.84 0.80 ± 0.01 0.81 ± 0.02 0.80 ± 0.03 
Table 4. Naloxone HCl instant disintegrating tablet specification and stability data after 9 months; 3 batches each n=2, thus 6 data points were used for each 




Figure 1s: Peak area of the mannitol recrystallization peak measured in the cooling cycle by differential scanning 


























Sodium Bicarbonate Content % w/w 
Data points average of n =3; error bars = s.d. 
Peak area = -20.3[NaHCO3] + 220.9 (r
2
 = 0.9) 
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Figure 2s: Disintegration of the naloxone instant disintegrating tablet compared to a Zydis® based formulation, 
marketed as Imodium Instants® (containing 2mg loperamide HCl), at 37
o
C and 0.7 mL of phosphate buffered 
saline. The Imodium Instants® tablets produced a cloudy suspension with 46% of the matrix remaining at 30 
seconds, while the novel naloxone instant disintegrating tablet generated an almost clear suspension with 10% of the 
matrix remaining 4.8 seconds and by 10 seconds only 6% of the naloxone instant disintegrating tablet matrix 





































 Imodium instants ®.
 Naloxone instant disintegrating tablet.
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Table 1S Summary of the f2 test for disintegration profiles with different temperatures and volumes. f2 ≥ 50 shows 
high similarity between the profiles. Low similarities are only seen between 25 
o
C and other temperatures. While 
discrimination against volume shows low similarities between all volumes with the exception of 0.2 and 0.1 mL     















C 57.6 High 
0.7 mL 
0.4 mL 28.36 Low 
33 
o
C 63.32 High 0.2 mL 19.13 Low 
25 
o






C 57.6 High 
0.4 mL 
0.7 mL 28.36 Low 
33 
o
C 72.83 High 0.2 mL 35.26 Low 
25 
o






C 63.32 High 
0.2 mL 
0.7 mL 19.13 Low 
35 
o
C 72.83 High 0.4 mL 35.26 Low 
25 
o






C 19.78 Low 
0.1 mL 
0.7 mL 17.09 Low 
35 
o
C 22.74 Low 0.4 mL 27.89 Low 
33 
o
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